Neurizon Therapeutics has received a positive opinion for Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency for NUZ-001 in Amyotrophic Lateral Sclerosis (ALS). This designation provides 10 years of market exclusivity in Europe upon product approval, offering significant regulatory and commercial benefits. The company is advancing NUZ-001 through a Phase 2/3 clinical study as part of the HEALEY ALS Platform Trial, with patient enrollment set to begin in early H1 CY2025. The positive opinion from the EMA further supports the potential of NUZ-001 to address urgent unmet needs in ALS globally. <br/><br/>By securing OMPD and Orphan Drug Designation from the US FDA, Neurizon now has market exclusivity across major markets for ALS treatment. This recognition underscores the significant potential of NUZ-001 to provide a meaningful therapeutic option for ALS patients. The company looks forward to continued engagement with regulators as it progresses in delivering innovative treatments for this devastating disease. For more information and to engage with us, please visit our Investor Hub for questions, comments, and video summaries of key announcements. We are committed to advancing treatments for neurodegenerative diseases and creating new horizons for patients and families.